3 Healthcare Stock Stories for Midweek Investment Wellness

| + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

Cerus Corporation (NASDAQ:CERS): Closing price $5.22

On Wednesday, Cerus announced that the FDA has accepted its proposed modular Premarket Approval application shell for review of the INTERCEPT Blood System for platelets. A PMA shell is a description of the application process that defines the structure, content and timing of each module. The agency and the applicant must agree on a shell before initiation of a modular PMA submission.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

CERS

AcelRx Pharmaceuticals (NASDAQ:ACRX): Closing price $6.02

The firm has reported top-line results showing that a placebo-controlled, dose-finding, Phase 2 evaluation of its investigational single-dose sublingual sufentanil NanoTab for acute pain, ARX-04, successfully attained its primary endpoint. Results indicated that patients receiving 30 mcg sufentanil NanoTab doses, administered by a healthcare professional, not more frequently than once per hour, experienced significantly more pain reduction as measured by Summed Pain Intensity Difference, to baseline during the 12-hour study period (SPID-12) than did placebo-treated patients. AcelRx is a specialty pharmaceutical firm concentrated on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

ACRX

BioMarin Pharmaceutical (NASDAQ:BMRN): Closing price $62.30

BioMarin on Wednesday announced the submission of a Marketing Authorization Application to the European Medicines Agency for Vimizim (BMN-110, elosulfase alfa), which is an enzyme replacement therapy under study for the treatment of patients suffering from the rare lysosomal storage disorder Mucopolysaccharidosis Type IVA (MPS IVA), also called Morquio A Syndrome. A Biologics License Application for Vimizim was submitted to the FDA in March.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

BMRN

Investing Insights: Will UnitedHealth Group Surge Higher?

More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business